Mirum Pharmaceuticals

OverviewSuggest Edit

Mirum Pharmaceuticals is a company creating therapies for patients with liver diseases. The company specializes in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It aims to address the underlying cause of symptoms and liver damage with the approach based on data from clinical trials.

TypePublic
Founded2018
HQFoster City, US
Websitemirumpharma.com

Latest Updates

Employees (est.) (Jul 2019)24
Job Openings10
Share Price (Nov 2020)$20 (+6%)
Cybersecurity ratingAMore

Key People/Management at Mirum Pharmaceuticals

Chris Peetz

Chris Peetz

President & Chief Executive Officer
Laura Brege

Laura Brege

Board Member
Ian Clements

Ian Clements

Chief Financial Officer
Lara Longpre

Lara Longpre

Chief Development Officer
Patrick Heron

Patrick Heron

Managing General Partner, Frazier Healthcare Partners
Peter Radovich

Peter Radovich

Chief Operating Officer
Show more

Mirum Pharmaceuticals Office Locations

Mirum Pharmaceuticals has an office in Foster City
Foster City, US (HQ)
950 Tower Ln #1050
Show all (1)

Mirum Pharmaceuticals Financials and Metrics

Mirum Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(23.3m)

EBIT (Q2, 2020)

(23.6m)

Market capitalization (20-Nov-2020)

515.1m

Closing stock price (20-Nov-2020)

20.0

Cash (30-Jun-2020)

83.0m

EV

435.5m
Mirum Pharmaceuticals's current market capitalization is $515.1 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

585.0k11.8m

R&D expense

2.3m43.0m

Operating expense total

17.4m54.7m

EBIT

(17.4m)(54.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.3m2.4m3.7m4.7m5.0m

R&D expense

4.9m11.6m12.2m17.3m18.6m

Operating expense total

6.2m14.0m15.9m22.0m23.6m

EBIT

(6.2m)(14.0m)(15.9m)(22.0m)(23.6m)
Annual
USDFY, 2018FY, 2019

Cash

52.0m12.0m

Prepaid Expenses

12.0k2.7m

Current Assets

52.0m119.4m

PP&E

1.4m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.5m41.8m30.8m72.0m83.0m

Prepaid Expenses

263.0k666.0k3.1m2.9m2.7m

Current Assets

49.8m84.9m129.3m162.4m152.1m

PP&E

453.0k460.0k631.0k1.4m1.4m
Annual
USDFY, 2018FY, 2019

Net Income

(17.3m)(52.6m)

Depreciation and Amortization

139.0k

Accounts Payable

2.4m

Cash From Operating Activities

(373.0k)(39.4m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(6.0m)(19.5m)(34.6m)(21.3m)(44.6m)

Depreciation and Amortization

43.0k80.0k73.0k143.0k

Accounts Payable

3.7m

Cash From Operating Activities

(2.4m)(10.4m)(25.7m)(18.4m)(35.3m)
USDFY, 2018

Financial Leverage

-3 x
Show all financial metrics

Mirum Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Mirum Pharmaceuticals AG

Mirum Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Mirum Pharmaceuticals Online and Social Media Presence

Embed Graph

Mirum Pharmaceuticals News and Updates

VC-backed Mirum Pharmaceuticals debuts IPO

Foster City, California-based Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symb…

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

FOSTER CITY, Calif., July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at...

Mirum Pharmaceuticals Blogs

Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will participate in the following

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat Content Import Sun, 11/15/2020 - 18:01 Mirum Pharmaceuticals Announces Data Presented During AASLD Highl…

Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

Maralixibat data highlights the relationship between the reduction of serum bile acids and pruritus intensity, improved growth, and other quality of life measures. Analysis of the natural variability of pruritus in children with Alagille syndrome demonstrates persistent severity.
Show more

Mirum Pharmaceuticals Frequently Asked Questions

  • When was Mirum Pharmaceuticals founded?

    Mirum Pharmaceuticals was founded in 2018.

  • Who are Mirum Pharmaceuticals key executives?

    Mirum Pharmaceuticals's key executives are Chris Peetz, Laura Brege and Ian Clements.

  • How many employees does Mirum Pharmaceuticals have?

    Mirum Pharmaceuticals has 24 employees.

  • Who are Mirum Pharmaceuticals competitors?

    Competitors of Mirum Pharmaceuticals include Vericel, MCRC and Quellis Biosciences.

  • Where is Mirum Pharmaceuticals headquarters?

    Mirum Pharmaceuticals headquarters is located at 950 Tower Ln #1050, Foster City.

  • Where are Mirum Pharmaceuticals offices?

    Mirum Pharmaceuticals has an office in Foster City.

  • How many offices does Mirum Pharmaceuticals have?

    Mirum Pharmaceuticals has 1 office.